5WBH image
Deposition Date 2017-06-29
Release Date 2017-12-20
Last Version Date 2023-10-04
Entry Detail
PDB ID:
5WBH
Keywords:
Title:
Structure of the FRB domain of mTOR bound to a substrate recruitment peptide of S6K1
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Host Organism:
Method Details:
Experimental Method:
Resolution:
1.75 Å
R-Value Free:
0.21
R-Value Work:
0.19
R-Value Observed:
0.19
Space Group:
P 2 21 21
Macromolecular Entities
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Serine/threonine-protein kinase mTOR
Gene (Uniprot):MTOR
Chain IDs:A, B, C, D, E
Chain Length:102
Number of Molecules:5
Biological Source:Homo sapiens
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Ribosomal protein S6 kinase beta-1
Gene (Uniprot):RPS6KB1
Chain IDs:F (auth: W)
Chain Length:26
Number of Molecules:1
Biological Source:Homo sapiens
Primary Citation
Mechanisms of mTORC1 activation by RHEB and inhibition by PRAS40.
Nature 552 368 373 (2017)
PMID: 29236692 DOI: 10.1038/nature25023

Abstact

The mechanistic target of rapamycin complex 1 (mTORC1) controls cell growth and metabolism in response to nutrients, energy levels, and growth factors. It contains the atypical kinase mTOR and the RAPTOR subunit that binds to the Tor signalling sequence (TOS) motif of substrates and regulators. mTORC1 is activated by the small GTPase RHEB (Ras homologue enriched in brain) and inhibited by PRAS40. Here we present the 3.0 ångström cryo-electron microscopy structure of mTORC1 and the 3.4 ångström structure of activated RHEB-mTORC1. RHEB binds to mTOR distally from the kinase active site, yet causes a global conformational change that allosterically realigns active-site residues, accelerating catalysis. Cancer-associated hyperactivating mutations map to structural elements that maintain the inactive state, and we provide biochemical evidence that they mimic RHEB relieving auto-inhibition. We also present crystal structures of RAPTOR-TOS motif complexes that define the determinants of TOS recognition, of an mTOR FKBP12-rapamycin-binding (FRB) domain-substrate complex that establishes a second substrate-recruitment mechanism, and of a truncated mTOR-PRAS40 complex that reveals PRAS40 inhibits both substrate-recruitment sites. These findings help explain how mTORC1 selects its substrates, how its kinase activity is controlled, and how it is activated by cancer-associated mutations.

Legend

Protein

Chemical

Disease

Primary Citation of related structures